Update description of client company

I work for the IR firm supporting Verastem, Inc. We would like to update the company description on the website as it is out-of-date.  Please see below desired text.  Please contact me at janet@argotpartners.com for any questions or to verify.

Verastem, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of drugs to treat cancer by the targeted killing of cancer stem cells. Its commercial product, duvelisib, targets the Phosphoinositide 3-kinase signaling pathway; and its leading product candidate, defactinib, is a targeted inhibitor of the Focal Adhesion Kinase signaling pathway. It evaluates its compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg and Christoph H. Westphal on August 4, 2010 and is headquartered in Cambridge, MA.